Skip to main content
The Maple Markets

New York Stock Exchange (NYSE) · HAE · ISIN US4050241003

Haemonetics Corporation

104.68 USD

+0.31(+0.30%)up

Previous close · Oct 2, 16:00 ET

Data last updated: (2 d ago)· Delayed exchange data

Sign in to add to portfolio

Haemonetics Corporation (HAE) trades on New York Stock Exchange (NYSE) and operates in the Medical - Devices industry. Its market capitalisation is approximately 4.76B USD. The company reports around 3,009 employees. Its ISIN is US4050241003. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Checking today's session…

Key facts

Exchange

New York Stock Exchange (NYSE)

ISIN

US4050241003

Sector

Healthcare

Industry

Medical - Devices

Country

US

Market cap

4.76B USD

Employees

3.01K

Previous close

104.37 USD

Day range

103.92 – 105.70

52-week range

48.17 – 110.45

Volume

328.57K

50-day average

98.88 USD

200-day average

75.02 USD

Asset type

Equity

About Haemonetics Corporation

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Company website

Frequently asked

+
What is the HAE share price today?
This page shows the latest available Haemonetics Corporation (HAE) price with its change against the prior close. Values are delayed or previous-close, not real-time.
+
Where is Haemonetics Corporation listed?
Haemonetics Corporation trades on New York Stock Exchange (NYSE) under the symbol HAE, ISIN US4050241003.
+
How large is Haemonetics Corporation?
Its market capitalisation is approximately 4.76B USD, based on the latest available price and share count from our data provider.

All Haemonetics Corporation data comes from exchange and provider feeds for New York Stock Exchange (NYSE) and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.

We use necessary cookies to run the site and, only with your permission, analytics cookies to understand what readers use. Cookie policy